Here, we used this strategy in the context of non-manifesting carriers of the LRRK2 G2019S mutation and identified a low-frequency variant in cyclin G-associated kinase (GAK) that acts as a protective factor on both the appearance of disease-related phenotypes in vitro and delaying AAO in PD patients. Here, LRRK2 is linked to Parkinson disease.